Close
Adolescent and Young Adult Cancer Program
Adolescent and Young Adult Cancer Program
Search result for "Solr search content"
Search Result for "*:*"
Story
Cracking cancer’s code: New research identifies novel drug target for acute myeloid leukemia treatment
Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at just 30% on average, according to the National Cancer Institute. Factors in the development of AML are diverse with many different drivers. A longtime goal for scientists in this field is finding a single drug that can treat all types of AML.
Story
CPRIT awards UT Health San Antonio $3.2 million to accelerate cancer research, launch novel clinical trial
The University of Texas Health Science Center at San Antonio (UT Health San Antonio) received more than $3.19 million in new academic research awards as part of the latest $68 million funding round announced on February 19 by the Cancer Research Prevention Institute of Texas (CPRIT). The state agency, which focuses on the fight […]
Story
Targeted drug offers hope for safe, effective senolytic treatment for liver disease, cancer
San Antonio has one of the highest rates of metabolic dysfunction-associated steatotic liver disease (MASLD) in the United States, largely driven by high rates of obesity and diabetes in the region. This chronic liver condition can lead to serious health conditions including severe liver fibrosis or cirrhosis and liver cancer, posing a significant public health […]
Cancer Treatment
Trans-Oral Robotic Surgery (TORS)
Doctors at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, deliver advanced therapies for cancers affecting the tonsils and base of the tongue. We perform trans-oral robotic surgery (TORS), which offers patients meticulous care and a potentially quicker return to daily activities.
provider
Sahar Heydari, MPAS, PA-C Hematology-Oncology, Physician Assistant
Clinical Trial
A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL217 in Patients with Advanced Solid Tumors
Dose-Escalation Part (Part 1)Primary Objectives:•To assess the safety and tolerability of YL217 in patients with advanced solid tumors•To determine the maximum tolerated dose (MTD) of YL217 in patients with advanced solid tumorsBackfill Part (Part 2)Primary Objectives:•To further evaluate the safety and tolerability of YL217 in patients with advanced solid tumors•To determine the recommended dose(s) for expansion (RDE(s)) of YL217 in patients with advanced solid tumorsDose-Expansion Part (Part 3)Primary Objectives:•To further evaluate the efficacy of YL217 at the RDE(s) in patients with the selected advanced solid tumors such as colorectal adenocarcinoma, gastric, esophageal or gastroesophageal junction adenocarcinoma, and pancreatic adenocarcinoma•To determine the recommended phase 2 dose (RP2D) of YL217
Clinical Trial
NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)
This phase III trial compares the effect of adding radiation therapy to usual care on the occurrence of bone-related complications in cancer patients with high-risk bone metastases that are not causing symptoms (asymptomatic). High-risk bone metastases are defined by their location (including hip, shoulder, long bones, and certain levels of the spine), or size (2 cm or larger).